Business
Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
– New MGTA-117 antibody-drug conjugate (ADC) clinical candidate for conditioning demonstrated broad therapeutic index in data highlighted in oral
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n– New MGTA-117 antibody-drug conjugate (ADC) clinical candidate for conditioning demonstrated broad therapeutic index in data highlighted in oral presentation at Transplant and Cellular Therapies (TCT) conference; advancing MGTA-117 to generate clinical data in 2021–\n\n\n–Reported first-ever successful gene therapy transplant of non-human primates with targeted single-agent CD117-ADC with no chemotherapy at ASH annual meeting and in best abstract at TCT–\n\n\n– Completed dosing in Phase 1 MGTA-145 trial, demonstrating rapid, single-day first line stem cell mobilization and collection; met all primary and secondary endpoints and presented data in oral presentation at TCT–\n\n\n–Presented first preclinical immune reset data with CD45-ADC at the American College of Rheumatology (ACR) annual meeting –\n\n\n– Presented additional data from Phase 2 study of MGTA-456 showing clinically meaningful durable benefits for patients with inherited metabolic disorders at TCT–\n\n\n–Ended year with $145.7 million in cash, cash equivalents and marketable securities –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights.\n\n\n“2019 was a year marked by crucial progress towards our vision of immune reset, including the advancement of our two lead conditioning programs and our two clinical programs. We generated unprecedented data from our ADC-based targeted conditioning platform, and we are particularly pleased with our new MGTA-117 clinical candidate for targeted conditioning for stem cell transplant or gene therapy. Results presented last month at the TCT conference highlighted the potency, safety and broad therapeutic index of MGTA-117, well above that of currently approved ADCs at this stage of development. We look forward to moving this program into the clinic with initial clinical data expected in 2021,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta. “We also presented updated clinical data for our first-line stem cell mobilization program, MGTA-145. We have completed dosing in the Phase 1 trial and are moving forward with multiple Phas...